Q-omics provides the consensus-scored SLBP profile across patient tissues and cancer cell-line models. SLBP expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SLBP is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SLBP protein abundance shows 21,032 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where SLBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLBP survival associations across molecular data types. SLBP RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLBP RNA expression–survival associations across cancer types. High SLBP expression shows unfavorable associations in MESO, ACC, KIRP and UVM, but favorable associations in UCS and UCEC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SLBP RNA expression.
This table summarizes SLBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLBP shows higher tumor expression in HNSC, BLCA, LUAD, LIHC, COAD and STAD. The HNSC box plot shows higher SLBP RNA expression in tumor versus normal tissue (log2 FC = +0.907, t-test p < 0.001).
This table shows molecular features associated with SLBP in patient tissues and cancer cell lines. In patient samples, SLBP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
